Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 42290037

Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.

Regina Castaneda·Dima Bechenati·Rene de J Rivera Gutierrez·Maria A Espinosa·Jose Villamarin·Elif Tama·Nancy Safwan·Sima Fansa·Alfredo Verastegui·Allyson W McNally·Jesse L Meek·Kristin C Cole·Stacey J Winham·Tamim I Rajjo·Andres Acosta·Stephanie S Faubion·Chrisandra L Shufelt·Maria D Hurtado Andrade
View original source ↗Export metadata ↓

Abstract

OBJECTIVE: This study assessed the impact of sex and age on weight loss outcomes in patients receiving tirzepatide in real-world clinical practice. METHODS: We conducted a retrospective cohort study of adults with overweight or obesity who initiated tirzepatide at Mayo Clinic between June 2022 and May 2024 and completed &#x2265;&#x2009;12&#x2009;months of continuous therapy. Primary outcome was total body weight loss percentage (TBWL%) at 15&#x2009;months, stratified by sex and age groups (&#x2264;&#x2009;45, 46-59, &#x2265;&#x2009;60&#x2009;years). RESULTS: Among 1039 patients (57% women; mean age 56&#x2009;&#xb1;&#x2009;11&#x2009;years), women achieved significantly greater TBWL% than men after 15&#x2009;months of treatment (15.1% vs. 10.7%, p&#x2009;<&#x2009;0.001). Patients aged &#x2264;&#x2009;45&#x2009;years had greater weight loss than those &#x2265;&#x2009;60&#x2009;years (15.1% vs. 12.3%, p&#x2009;=&#x2009;0.024). In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain-promoting medications, and higher tirzepatide dosage. Age was not an independent predictor. CONCLUSIONS: Sex, but not age, predicted weight loss with tirzepatide among individuals using the medication continuously for &#x2265;&#x2009;12&#x2009;months. These findings underscore the importance of incorporating sex-specific considerations into personalized obesity treatment strategies.

Explore related subjects

HumansTirzepatideRetrospective StudiesFemaleWeight LossObesityMaleMiddle AgedSex FactorsAge FactorsTreatment OutcomeAnti-Obesity AgentsAgedOverweightAdultageobesitysex differencestirzepatideweight lossJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Regina Castaneda, Dima Bechenati, Rene de J Rivera Gutierrez, Maria A Espinosa, Jose Villamarin, Elif Tama, Nancy Safwan, Sima Fansa, Alfredo Verastegui, Allyson W McNally, Jesse L Meek, Kristin C Cole, Stacey J Winham, Tamim I Rajjo, Andres Acosta, Stephanie S Faubion, Chrisandra L Shufelt, Maria D Hurtado Andrade. 2026-06-14. Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.. https://doi.org/10.1002/oby.70231

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗
PubMed2027

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗
PubMed2027

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗